Cohance

September 3, 2026

To	To
BSE Limited	National Stock Exchange of India Limited
25th Floor, P. J. Towers,	Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai - 400 001	Bandra (E), Mumbai – 400 051
Scrip Code: 543064	**Scrip Symbol: COHANCE**

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In continuation of the Company's disclosures dated December 7, 2024 and December 21, 2024 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 **("SEBI Listing Regulations"),** Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) (the "**Company**" or "**Cohance**") wishes to inform that, in accordance with the in-principle approval accorded and powers delegated by the Board of Directors (**"Board"**) of the Company, the Investment, Banking and Authorisations Committee (IBA Committee) of the Board, at its meeting held today, i.e. September 3, 2026, has considered and approved the following as part of a proposed reorganisation at:

(i) **NJ Bio, Inc**. **("NJ Bio"**), a subsidiary of the Company: for the acquisition of an additional 244,587 shares of common stock in NJ Bio at USD 53.00 per share (aggregate consideration of approximately USD 13 million), increasing the Company's stake from 56% to 67.3%. Dr. Naresh Jain will continue as CEO of NJ Bio, retaining 32.7% of NJ Bio's equity.

(ii) **Aruka Bio, Inc**. (**"Aruka Bio"**), a step-down associate of the Company: for subscribing (either directly or through its nominated subsidiary) shares of Aruka Bio, which is an innovative platform focusing on novel ADC therapies, for approximately USD 5 million, acquiring approximately 65%. Dr. Naresh Jain will also assume the role of CEO at Aruka Bio.

This reorganisation reinforces Cohance's commitment to the ADC space through closer integration of NJ Bio's customer-facing capabilities with Cohance's manufacturing platform, while positioning Aruka Bio to advance its proprietary pipeline through potential development partnerships. The closer integration of NJ Bio with Cohance is expected to strengthen business performance across the combined platform over time.

The NJ Bio transaction is subject to the execution of amended and restated agreements, and the Aruka Bio transaction is subject to the execution of definitive agreements, in each case subject to receipt of applicable regulatory approvals and customary closing conditions.

A copy of the press release being issued in this regard is enclosed herewith.

The disclosures pursuant to Regulation 30 of the SEBI Listing Regulations read with Part A of Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are set out in **Annexure-A (NJ Bio)** and **Annexure-B (Aruka Bio)**.

The IBA Committee meeting commenced at 4.00 p.m. (IST) and was concluded at 4.55 p.m. (IST).

This is for your information and records.

Thanking you.

Yours faithfully,

For **Cohance Lifesciences Limited**
(formerly, Suven Pharmaceuticals Limited)

SISIRA KUMAR MISHRA

Digitally signed by SISIRA KUMAR MISHRA
Date: 2026.09.03 19:45:45 +05'30'

Sisir K Mishra
Company Secretary & Compliance Officer

Encl: As above.

Cohance

Cohance Lifesciences advances its ADC strategy

Investment of USD 18 million in NJ Bio and Aruka Bio

September 03, 2026: Cohance Lifesciences Limited today announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an additional investment of USD 13 million in NJ Bio and a controlling investment of USD 5 million in Aruka Bio. Both the transactions will be funded through internal accruals.

The re-organisation establishes distinct priorities: deeper integration of NJ Bio's customer-facing services with Cohance, and focused development of Aruka's proprietary pipeline through potential partnerships.

NJ Bio: planned succession, continued founder engagement

Cohance will increase its common-equity ownership in NJ Bio from 56.0% to 67.3%, acquiring the entire holdings of Ms. Priyashri Nayak, and the Jain Family Irrevocable Trust. Dr. Jain will retain 32.7%.

Dr. Jain will continue to lead NJ Bio while also advancing Aruka's pipeline and partnership initiatives.

NJ Bio will remain focused on customer-facing contract research, development and manufacturing services. Closer integration will combine its payload-linker and bioconjugation expertise with Cohance's manufacturing capabilities to support customers end-to-end CRDMO development through commercial supply. This integration is expected to strengthen business performance across the combined platform over time.

Aruka Bio: control of the platform, development with partners

Aruka Bio, Inc. is a private biotechnology company based in Princeton, New Jersey, focused on developing next-generation antibody-drug conjugates. Its lead program is currently at the preclinical stage.

Cohance's USD 5 million equity investment will fund the buyout of other existing shareholders and convertible noteholders along with working capital.

Following completion and Dr. Jain's upfront equity grant, Aruka will be owned 65% directly by Cohance, 25% by NJ Bio and 10% by Dr. Jain. These percentages are before further dilution from Dr. Jain's performance-linked equity award.

Aruka will become Cohance's direct subsidiary. The investment consolidates control of Aruka's proprietary ADC platform, positioning it to pursue co-development, licensing and other collaborations with pharmaceutical and biotechnology partners as its pipeline progresses.

This follows a review of NJ Bio's performance and integration with Cohance since the original investment in December 2024, which identified an opportunity to strengthen commercial alignment between the two businesses as NJ Bio expands its GMP CDMO services and to give dedicated leadership focus to Aruka's novel drug development pipeline.

Completion is expected by the end of September 2026, subject to definitive agreements, applicable approvals and customary closing conditions.

Dr. Naresh Jain, Founder and CEO, NJ Bio, said: *"I will work across both businesses—supporting NJ Bio's growth and an orderly leadership handover, while working together with Cohance in advancing Aruka's pipeline and exploring development partnerships. Thereafter, I will focus full-time on Aruka as CEO, while continuing to support NJ Bio as a strategic advisor."*

Umang Vohra, Executive Chairman and Group CEO, Cohance Lifesciences, said: *"This reorganisation gives each business a clear focus: strengthening NJ Bio's customer offering through closer integration with Cohance and creating the opportunity for Dr Jain to lead Aruka's next phase. This integration is expected to strengthen business performance across the combined platform over time"*

-ENDS-

About Cohance Lifesciences

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. Leveraging a combined platform with state-of-the-art facilities in India and the U.S., Cohance delivers integrated solutions from early development to commercial supply for leading global pharma companies.

For more information, please contact: www.cohance.com

Cyndrella Carvalho, Head - Investor Relations,
Cohance Lifesciences Limited
Tel: 040 2354 3311
Email: cyndrella.carvalho@cohance.com

Gavin Desa / Konpal Pali
CDR India
Tel: +91 98206 37649/ +91 76619 08341
Email: gavin@cdr-india.com; konpal@cdr-india.com

Annexure-A

Reorganization at NJ Bio

Sl	Particulars	Details
a.	Name of the target entity, details in brief such as size, turnover etc.	**Name of the Target**: NJ Bio, Inc (NJ Bio) having its registered office at 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808 and corporate office at 350 Carter Road, Princeton, NJ 08540. **Details of the Target**: NJ Bio is an Antibody Drug Conjugate ("ADC") focused Contract Research, Development, and Manufacturing Organization ("CRDMO") and one of the leading global players with end-to-end capabilities across payload-linker synthesis, bioconjugation and analytical services, providing customized ADC solutions that accelerate customers' discovery and development. **Turnover**: • CY2023: USD 20.6 million • CY2024: USD 32.6 million • CY2025: USD 23.5 million
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The acquisition would fall within related party transaction. NJ Bio is a subsidiary of the Company (the Company currently holds 56% of NJ Bio's equity share capital). The promoter/ promoter group/ group companies of the Company do not have any direct interest in NJ Bio, other than through the Company as aforesaid. The acquisition is at arm's length.
c.	Industry to which the entity being acquired belongs	Pharmaceutical / Chemical Compounds CRDMO
d.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Cohance, along with its subsidiaries/affiliates, is engaged in the contract development, manufacture and sale of drug products and other allied activities. NJ Bio, Inc. is amongst the few CRDMOs in the high growth ADC and broader 'XDC' (other conjugation-based therapies) space. The acquisition of an additional stake reinforces Cohance's commitment to the ADC space and will drive a stronger partnership with customers, positioning NJ Bio and Cohance's capabilities together to create meaningful value.
e.	Brief details of any governmental or regulatory approvals required for the acquisition;	The acquisition will be in accordance with the applicable provisions of the FEMA (Overseas Investment) Regulations, 2022 read with the rules and circulars made thereunder. Further, the Company will make applicable regulatory filings with the relevant authorities, as may be required under applicable laws.

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharastra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com

f.	Indicative time period for completion of the acquisition;	The Company expects to complete the acquisition before end of September 2026, subject to the completion of customary closing conditions. Further, the Company shall acquire the remaining stake after December 2029 under a put and call option mechanism, upon completion of which the Company will hold 100% of NJ Bio's equity share capital.
g.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration (through internal accruals) for the secondary acquisition of shares from certain existing shareholders of NJ Bio.
h.	Cost of acquisition and/or the price at which the shares are acquired;	The aggregate consideration is USD 12,963,111 for the secondary acquisition of 244,587 shares of common stock at USD 53.00 per share from Dr Naresh Jain shareholding group, comprising: (i) 142,000 shares from Ms. Priyashri Nayak for USD 7,526,000; and (ii) 102,587 shares from the Jain Family Irrevocable Trust for USD 5,437,111.
i.	Percentage of shareholding / control acquired and / or number of shares acquired	Upon completion of the acquisition, the Company will hold 67.3% of NJ Bio's equity share capital. NJ Bio will continue to be a subsidiary of the Company.
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	**<u>Brief background and line of business</u>**: NJ Bio, Inc. is an ADC / 'XDC' focused CRDMO and one of the leading global players with end-to-end capabilities across payload-linker synthesis, bioconjugation and ADCs characterization, providing customized ADC solutions that accelerate customers' discovery and development. **Date of Incorporation**: NJ Bio, Inc. (formerly known as NJ Biopharmaceuticals LLC), was incorporated as a limited liability company under applicable laws on 23 October 2017 in Bristol, Pennsylvania, USA, and was subsequently converted to an incorporated corporation, in the name of NJ Bio, Inc., on 01 August 2022 in Delaware, USA. **Turnover of last 3 years**: • CY2023: USD 20.6 million • CY2024: USD 32.6 million • CY2025: USD 23.5 million **Country in which the entity has presence**: Other than USA, NJ Bio has business operations in India through a subsidiary entity, NJBIO India Pharmaceutical Private Limited.

Reorganization at Aruka Bio

Sl	Particulars	Details
a.	Name of the target entity, details in brief such as size, turnover etc.	**Name of the Target**: Aruka Bio, Inc. (Aruka Bio) having its registered office 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808 and corporate office at 350 Carter Road, Princeton, NJ 08540. **Details of the Target**: The Target is an innovative company working on novel Payload-linker and ADC platforms and is based in Princeton, New Jersey **Turnover**: • CY2023: Nil • CY2024: Nil • CY2025: Nil
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The acquisition would fall within related party transaction. The promoter/ promoter group/ group companies of the Company do not have any direct interest in the Target, other than through the Company's subsidiary NJ Bio as aforesaid. The Proposed Transaction is being done at "arm's length" basis.
c.	Industry to which the entity being acquired belongs	Pharmaceutical
d.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Cohance, along with its subsidiaries/affiliates, is engaged in the contract development, manufacture and sale of drug products and other allied activities. Aruka Bio is an innovative company working on novel Payload-linker and ADC platforms. ADCs are a key focus area for Cohance making this a strong strategic fit. Cohance's equity investment of approximately USD 5 million will be utilized to redeem existing investors (approximately USD 4.75 million) and for working capital requirements (approximately USD 0.25 million)

e.	Brief details of any governmental or regulatory approvals required for the acquisition;	The acquisition will be in accordance with the applicable provisions of the FEMA (Overseas Investment) Regulations, 2022 read with the rules and circulars made thereunder. Further, the Company (or its nominated subsidiary, as applicable) will make applicable regulatory filings with the relevant authorities, as may be required under applicable laws.
f.	Indicative time period for completion of the acquisition;	The Company (or its nominated subsidiary) expects to complete the Transaction before end of September 2026, subject to the completion of customary closing conditions.
g.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration through internal accruals.
h.	Cost of acquisition and/or the price at which the shares are acquired;	The consideration is approximately USD 5 million for subscription to 113,089 common equity shares of Aruka Bio.
i.	Percentage of shareholding / control acquired and / or number of shares acquired	The Company (or its nominated subsidiary) shall acquire 113,089 common equity shares of Aruka Bio, which as on the date of completion of the subscription shall correspond to approximately: (a) 57.8% equity shareholding in Aruka Bio on a fully diluted basis on closing of the Proposed Transaction; and (b) 65% on a non-diluted basis, where the dilution may be on account of restricted stock of the Chief Executive Officer of Aruka Bio. Post the Transaction, Aruka Bio will be a subsidiary of the Company or of its nominated subsidiary.
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	**Brief background and line of business**: The Target is an innovative company working on novel Payload-linker and ADC platforms and is based in Princeton, New Jersey **Date of Incorporation**: Aruka Bio, Inc. was incorporated as an incorporated corporation on 26 May 2023 in Delaware, USA **Turnover of last 3 years**: • CY2023: Nil • CY2024: Nil • CY2025: Nil **Country in which the entity has presence**: The Target has business operations in the USA